Capsules Ready in Time to Supply Pharmacy Joint Initiative in Q1 2018
TORONTO, ONTARIO–(Marketwired – Nov. 20, 2017) –
Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) (“Maricann” or the “Company”) through its wholly owned subsidiary, Maricann Inc. has commenced production of encapsulated cannabis oil, following receipt of its production license from Health Canada on November 17, 2017. Maricann expects patients to be able to order oil capsules starting in Q1 2018, subject to Health Canada’s issuance of the required license to sell.
Maricann Capsules are a critical innovation in medicinal cannabis therapy as they deliver medicine in a dosage form widely utilized in the pharmaceutical industry, provide precise dosing in each capsule, enhance patient compliance and will be formulated to support therapeutic efficacy. All natural cannabis extract will be delivered in a vegan capsule format, initially in four products: 15mg and 25mg cannabidiol (CBD) capsules and 5mg and 10mg THC capsules, allowing physicians and patients to more easily control dosing and choose the cannabinoid therapy they prefer. In parallel, Maricann will commence production of its exclusive and patented VesiSorb™ technology in capsule format. VesiSorb™ is approved in the delivery of other lipophilic (fat-soluble pharmaceutical and nutraceutical formulations) drugs by Health Canada, the US Food and Drug Administration and European Medicines Agency. Application of VesiSorb is not limited to capsules, but spans entire product categories of ingestibles, including capsules, edibles and functional beverages. See the VesiSorb difference in the following link: VesiSorb
Physicians and patients understand metered dose capsules, they’re a part of daily life. Vaporizing and smoking aren’t something people new to cannabis are familiar or comfortable with, so we believe that providing them with a treatment option in a delivery format they understand is compelling. Medicinal cannabinoids have anecdotally demonstrated therapeutic benefit for a wide range of symptoms; however, cannabinoids are nearly insoluble in water.
Ben Ward, CEO of Maricann
Their poor solubility and low dissolution rate in the aqueous gastrointestinal fluids and significant first-pass liver metabolism result in low and unpredictable oral cannabinoid bioavailability. Consequentially, cannabinoids will require high doses to reach therapeutic plasma concentrations, especially when ingested. At Maricann, we are focused on formulations that actually potentiate the components of the cannabis plant.
Maricann offers true differentiation with our full acquisition of the global rights for Vesisorb technology for phytocannabinoids (see press release dated August 22, 2017). Vesisorb is a proprietary patented lipid based nano-colloidal drug delivery technology that delivers standardized profiles of whole plant extracts, in convenient, microliter dosages with increased bioavailability, bioactivity and therapeutic potential. This is a major advancement in lipophilic drug delivery technology.
About Maricann Group Inc.
Maricann, which has federal licenses in Canada to cultivate, extract, formulate and distribute cannabis, is rapidly expanding its Canadian production, based in Norfolk County, Ontario, adding 22,245 kg of annual production of dry flower to come online in Q2 2018, with additional production planned. Maricann is focused on expanding capacity in a truly differentiated product offering, in support of its previously announced joint pharmacy initiative and future global export opportunities.
For more information about Maricann, please visit our website at www.maricann.com
